Himmelfarb Health Sciences Library, The George Washington University

Health Sciences Research Commons
Global Health Faculty Publications

Global Health

3-1-2017

Population-Based Pertussis Incidence and Risk
Factors in Infants Less Than 6 Months in Nepal.
Michelle M Hughes
Janet A Englund
Jane Kuypers
James M Tielsch
George Washington University

Subarna K Khatry
See next page for additional authors

Follow this and additional works at: https://hsrc.himmelfarb.gwu.edu/sphhs_global_facpubs
Part of the International Public Health Commons, and the Respiratory Tract Diseases Commons
APA Citation
Hughes, M., Englund, J., Kuypers, J., Tielsch, J., Khatry, S., Shrestha, L., LeClerq, S., Steinhoff, M., & Katz, J. (2017). Population-Based
Pertussis Incidence and Risk Factors in Infants Less Than 6 Months in Nepal.. Journal of Pediatric Infectious Diseases Society, 6 (1).
http://dx.doi.org/10.1093/jpids/piw079

This Journal Article is brought to you for free and open access by the Global Health at Health Sciences Research Commons. It has been accepted for
inclusion in Global Health Faculty Publications by an authorized administrator of Health Sciences Research Commons. For more information, please
contact hsrc@gwu.edu.

Authors

Michelle M Hughes, Janet A Englund, Jane Kuypers, James M Tielsch, Subarna K Khatry, Laxman Shrestha,
Steven C LeClerq, Mark Steinhoff, and Joanne Katz

This journal article is available at Health Sciences Research Commons: https://hsrc.himmelfarb.gwu.edu/sphhs_global_facpubs/222

Journal of the Pediatric Infectious Diseases Society

ORIGINAL ARTICLE

Population-Based Pertussis Incidence and Risk Factors in
Infants Less Than 6 Months in Nepal
Michelle M. Hughes,1 Janet A. Englund,2 Jane Kuypers,3 James M. Tielsch,4 Subarna K. Khatry,5 Laxman Shrestha,6 Steven C. LeClerq,1,5
Mark Steinhoff,7 and Joanne Katz1
1
Johns Hopkins Bloomberg School of Public Health, Department of International Health, Global Disease Epidemiology and Control, Baltimore, Maryland; 2University of
Washington, Seattle Children’s Hospital; 3University of Washington, Molecular Virology Laboratory, Seattle; 4George Washington University Milken Institute School of Public
Health, Department of Global Health, Washington, District of Columbia; 5Nepal Nutrition Intervention Project–Sarlahi, Kathmandu; 6Tribhuvan University Teaching Hospital,
Department of Paediatrics, Institute of Medicine, Maharajgunj, Kathmandu, Nepal; 7Cincinnati Children’s Hospital and Medical Center, Global Health Center, Ohio

Background. Pertussis is estimated to cause 2 percent of childhood deaths globally and is a growing public health problem in
developed countries despite high vaccination coverage. Infants are at greatest risk of morbidity and mortality. Maternal vaccination
during pregnancy may be effective to prevent pertussis in young infants, but population-based estimates of disease burden in infants
are lacking, particularly in low-income countries. The objective of this study was to estimate the incidence of pertussis in infants less
than 6 months of age in Sarlahi District, Nepal.
Methods. Nested within a population-based randomized controlled trial of influenza vaccination during pregnancy, infants
were visited weekly from birth through 6 months to assess respiratory illness in the prior week. If any respiratory symptoms had
occurred, a nasal swab was collected and tested with a multitarget pertussis polymerase chain reaction (PCR) assay. The prospective
cohort study includes infants observed between May 2011 and August 2014.
Results. The incidence of PCR-confirmed Bordetella pertussis was 13.3 cases per 1000 infant-years (95% confidence interval,
7.7–21.3) in a cohort of 3483 infants with at least 1 day of follow-up.
Conclusions. In a population-based active home surveillance for respiratory illness, a low risk for pertussis was estimated
among infants in rural Nepal. Nepal’s immunization program, which includes a childhood whole cell pertussis vaccine, may be
effective in controlling pertussis in infants.
Keywords. epidemiology; incidence; infants; Nepal; pertussis.

A resurgence of pertussis across age groups has occurred in
several countries in recent years [1]. Middle- and high-income
countries that use an acellular pertussis vaccine for the primary
vaccination series have been particularly affected [2, 3], and
infants and adolescents have experienced the greatest increase
[4]. Factors that may contribute to the increased risk of pertussis include rapidly waning immunity from those vaccinated with
acellular vaccines [1, 5, 6], asymptomatic transmission from individuals vaccinated with acellular vaccines [7], genetic adaption of
Bordetella pertussis [8], vaccination delay or refusal [9], improved
surveillance and laboratory capabilities [2], and overall increased
awareness of the continuing circulation of B pertussis [1].
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Some countries experiencing epidemic pertussis, including
the United States, United Kingdom, and Argentina, now recommend pertussis immunization in pregnancy and vaccination
of close contacts [10, 11] to protect the youngest infants from
pertussis before they can be vaccinated themselves [12]. Recent
data from maternal vaccination trials demonstrate the ability of
antibodies to be transferred from mothers to their infants in
pregnancy and their persistence in infants [13].
Global estimates of pertussis show the highest childhood
burden in Southeast Asia [14]. In this region, maternal pertussis
vaccination during pregnancy may be a way to protect infants,
similar to the approach using tetanus toxoid vaccine. However,
globally only 1 population-based estimate of pertussis in infants
from birth has been conducted (Senegal) [15], and surveillance
and laboratory capabilities in Asia are lacking [16, 17]. The
World Health Organization (WHO) recently recommended
that countries using whole cell pertussis vaccines continue to do
so in light of recent data indicating that acellular pertussis vaccines are less effective than whole cell pertussis vaccines [18].
Population-based data are needed, especially in low-income
settings, to provide a more accurate estimate of the burden of
pertussis in infants to inform childhood and maternal immunization policies [19, 20].
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We report on a prospective cohort study following infants
weekly in their homes to monitor for pertussis disease from
birth to age 6 months. The objective was to provide a population-based estimate of laboratory-confirmed pertussis
incidence in infants less than 6 months of age in the Sarlahi
District, Nepal.
METHODS
Settings and Population

The study was nested within 2 consecutive randomized controlled trials of maternal influenza vaccination during pregnancy set in the Sarlahi District, located in the central Terai
(low-lying plains) region of Nepal [21]. At the start of the trial,
prevalent pregnancies were identified through a census of all
households in the catchment area. For the duration of the trial,
field workers visited all households in the communities, every
5 weeks, where married women (15–40 years) resided, for surveillance of incident pregnancies. Once a pregnancy was identified, women provided consent and were enrolled. From April
25, 2011 through September 9, 2013, women between 17 and 34
weeks gestation were randomized and vaccinated with either an
influenza vaccine or placebo. The study was a population-based
prospective cohort of infants followed from birth through
6 months postpartum. Approval for the study was obtained from
the Institutional Review Boards at the Johns Hopkins Bloomberg
School of Public Health, Cincinnati Children’s Medical Center,
the Institute of Medicine at Tribhuvan University, Kathmandu,
and the Nepal Health Research Council. The trials are registered
at Clinicaltrials.gov (NCT01034254).

6 months postpartum who reported fever plus one additional
morbidity (cough, sore throat, nasal congestion, or myalgia).
All nasal swabs collected from infants were tested for B pertussis, Bordetella parapertussis, and Bordetella bronchispetica. Only
the nasal swabs of mothers whose infants tested positive for any
of these pathogens were tested for the same pathogens.
Laboratory Assays

Real-time polymerase chain reaction (PCR) testing was conducted at the University of Washington’s Molecular Virology
Laboratory according to previously published methods [23].
Two-target PCR was used to assess the presence of 3 Bordetella
species: B pertussis, B parapertussis, and B bronchiseptica.
The amplified targets were chromosomal repeated insertion
sequence IS481 (IS) and the polymorphic pertussis toxin ptxA
promoter region (PT).
After amplification, the melting points of the amplicons were
measured in an iCycler (Bio-Rad). A sample was interpreted as
positive when the target(s) had a melting temperature within
the species-specific acceptable range and a computed tomography ≤42. A sample was negative if none of the targets tested positive or a single positive target was not reproducible. Maternal
nasal swabs were tested for those mothers whose infants tested
positive for any Bordetella species
Polymerase chain reaction was also performed for several
viral infections (influenza, rhinovirus [RV], respiratory syncytial virus [RSV], bocavirus [BoV], human metapneumovirus,
coronavirus, adenovirus, and parainfluenza [1–4]) as previously
described [21].
Analytic Dataset

Data Collection

At baseline, information was collected on household structure,
socioeconomic status, and demographics. At enrollment, date
of last menstrual period and pregnancy history data were collected. As soon as possible after delivery, the mother and infant
were visited to collect detailed birth information including
infant weight and breastfeeding status. From birth through
6 months, postpartum infants were visited weekly by a field
worker, who recorded any infant respiratory symptoms in the
past 7 days. If an infant had any of the following symptoms,
a mid-nasal nylon flocked swab was collected: fever, cough,
wheeze, difficulty breathing, or ear infection. Starting on August
17, 2012, new symptoms, more specific for pertussis, were
added to the weekly morbidity visit: apnea, cyanosis, cough
with vomit, or whoop/whooping cough. The swabs were stored
for up to 1 week at room temperature in PrimeStore Molecular
Transport Medium (Longhorn Diagnostics LLC, Bethesda,
MD). In addition to these signs, mothers were asked which, if
any, infant vaccinations were received in the past 7 days, including pertussis vaccination [22]. Mid-nasal swabs were also collected on a weekly basis from mothers from enrollment through
34 • JPIDS 2017:6 (March) • Hughes et al
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Of 3693 women enrolled, 3646 infants were live born to 3621
women (Supplementary Figure 1). Infants were included in this
analysis if they were followed for any length of the follow-up
period (0 to 180 days); median total follow-up was 146 days
per infant (Supplementary Figure 2). The final dataset consists
of 3483 infants, contributing 1280 infant-years of observation,
with at least 1 follow-up visit during the first 6 months. This
includes infants from the entire trial period, both before and
after more pertussis-specific additions to the weekly symptom
questionnaire.
At baseline, data on household structure were gathered. At
enrollment, women reported their literacy status (binary) and
pregnancy history. The field workers identified their ethnicity
into 2 broad groups (Pahadi, a group originating from the hills;
or Madeshi, a group originating from north India) from names
and observation. Women were categorized as nulliparous or
multiparous. Responses to 25 questions about household construction, water and sanitation, and household assets were used
to develop an index to measure the socioeconomic status of
households. Binary variables for each of the 25 questions and a
mean SES score were calculated for each household.

Gestational age was measured using a woman’s report of date
of last menstrual period during pregnancy surveillance. Birth
weight was collected as soon as possible after birth using a digital scale (Tanita model BD-585, precision to nearest 10 grams).
Birth weights collected >72 hours after birth were excluded
from the analysis. Small for gestational age (SGA) was calculated using the sex-specific 10th percentile cutoff described by
Alexander et al [24] and the INTERGROWTH-21 standards
[25]. Women were asked within how many hours of birth
breastfeeding was initiated and binary breastfeeding categories
were created (≤1 hour versus >1 hour postdelivery).
Statistical Analysis

Incidence was calculated as the number of pertussis cases per
1000 infant-years at risk. Poisson exact 95% confidence intervals (CIs) were constructed. Characteristics of infant pertussis
cases were compared with nonpertussis cases using bivariate
Poisson regression. Characteristics of all pertussis respiratory
episodes were compared with nonpertussis respiratory episodes; t tests were used for continuous predictors and Fisher’s
exact tests were used for categorical associations due to the low
number of pertussis episodes. All statistical analyses were conducted in Stata/SE 14.1.
RESULTS

A total of 3483 infants had 4283 episodes of respiratory illness
between May 18, 2011 and April 30, 2014. Thirty-nine percent
(n = 1350) of infants experienced no respiratory episodes. The
incidence of respiratory illness was 3.6 episodes per infant-year
(95% CI, 3.5–3.7). Mean episode duration was 4.7 days (95%
CI, 4.6–4.9). A total of 3930 (92%) episodes were matched
to 1 or more pertussis-tested nasal swabs from 2026 infants
(Supplementary Figure 1).
Seventeen cases of B pertussis were identified from 19 nasal
swabs (nasal swabs were positive on 2 consecutive weeks for 2
infants). The incidence of PCR-confirmed B pertussis was 13.3
cases per 1000-infant years (95% CI, 7.7–21.3). Five cases of B
parapertussis were detected with an incidence of 3.9 cases per
1000 infant-years (95% CI, 1.3–9.1). No cases of B bronchiseptica were identified.
Bordetella Pertussis

The average pertussis episode duration was 8 days (range,
2–33) (Table 1). Mean age of onset of symptoms was 83 days
(range, 19–137) (median, 80; interquartile range, 63–109). The
most common symptoms were cough, difficulty breathing, and
cough with vomit. None of the additional symptoms related
to pertussis that were added in year 2 (cyanosis, apnea, cough
with vomit, and whoop) resulted in collection of nasal swabs
based solely on these additional symptoms. Pertussis episodes
were statistically significantly more likely to include difficulty

breathing, cough with vomit, and whoop compared with other
respiratory illness. Six infants had at least 1 pertussis vaccination before pertussis disease onset (three <2 weeks and three
>2 weeks before pertussis illness) with a mean of 18 days from
vaccination to illness compared with 49 days for nonpertussis
episodes (P = .03). Five infants received their first pertussis vaccination postpertussis disease onset, whereas 6 infants received
no pertussis vaccination in the first 180 days. Three fourths of
pertussis episodes were coinfected with at least 1 virus, with RV
and BoV the most common. Cases of pertussis were more likely
to be infected with BoV than respiratory cases due to causes
other than pertussis. The majority of cases occurred between
February 2013 and January 2014 (Figure 1).
No statistically significant differences between risk factors for pertussis and nonpertussis cases (Table 2) were documented. Given the low number of pertussis cases, the lack of
a statistical association is not evidence of nonassociation. No
deaths occurred in infants who had pertussis. Of the 8 mothers
of B pertussis-positive infants who had a nasal swab collected
(14 nasal swabs total) during their own follow-up, none were
positive for any pertussis species.
Bordetella Parapertussis

The 5 B parapertussis cases were primarily male whose mothers
were primiparous, literate, and Pahadi ethnicity (Supplementary
Table 1). No mothers of infants who had B parapertussis had a
nasal swab collected during follow-up.
The average B parapertussis episode duration was 4 days
(Supplementary Table 2). Mean age of onset of symptoms was
58 days with a range of 7–95 days. The most common symptoms were cough and wheeze. Rhinovirus and RSV were the
only coinfections observed. All B parapertussis cases occurred
between September 2011 and February 2012 (Figure 1).
DISCUSSION

A low incidence of pertussis and generally mild clinical presentation were found in infants <6 months in Nepal. To our
knowledge, this represents one of the first population-based
active surveillance of PCR-confirmed pertussis among young
infants in Asia. Acellular pertussis vaccine trials conducted in
the 1990s found the average pertussis incidence in the whole
cell vaccine groups ranged from 1 to 37 cases per 1000 infantyears [26]. Our finding of 13 B pertussis cases per 1000 infantyears was on the lower end of this range. In the United States
in 2014, the estimated pertussis incidence in infants less than
6 months was 2 cases per 1000 infant-years [27], much lower
than observed in our study; however, this passive surveillance system likely vastly underestimates pertussis incidence.
Thus, there is a need for active surveillance data such as ours.
Furthermore, given our highly sensitive case detection method,
many of our pertussis cases would likely not have been detected
Infant Pertussis Incidence in Nepal • JPIDS 2017:6 (March) • 35
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Table 1.

Comparison of Pertussis Episodes to Nonpertussis Episodes

Characteristic

Nonpertussis
Episodes

Pertussis
Episodes

(n = 3913)

(n = 17)

Proportion

Symptomsb
Cough
Difficulty breathing
Cough with vomit
Wheeze
Fever
Whoop
Apnea
Cyanosis
Ear Infection

71%

40%

65%

12%

50%

45%

47%

53%

47%

6%

33%

4%

17%

1%

8%

5%

6%

Age at episode start (days)
RV
BoV
PIV3
RSV
Influenza
MPV
CoV
PIV1
PIV2
PIV4
AdV
Vaccination
Received 1st pertussis vaccination

Proportion

62%

Episode duration (days)
Coinfections

Mean

.62
.05
.00
.99
.64
.01
.08
.09

5

8

91

83

50%

53%

5%

24%

4%

12%

9%

6%

5%

6%

5%

6%

8%

6%

2%

0%

1%

0%

2%

0%

2%

0%

38%

Days since vaccination

Mean P Valuea

.07
.54
.99
.01
.17
.99
.55
.57
.99
.99
.99
.99
.99

35%
49

.59

18

0.99
0.03

Abbreviations: AdV, adenovirus; BoV, bocavirus; CoV, coronavirus; MPV, human metapneumovirus; PIV, parainfluenza; RSV, respiratory syncytial virus; RV, rhinovirus.
a
t tests were used for continuous predictors and Fisher’s exact tests were used for categorical predictors;
statistical significance of P < .05 indicated in bold.
b
Cough with vomit, apnea, whoop, and cyanosis were only captured in year 2; denominator for these symptoms was 2034 episodes.

in the previous acellular pertussis vaccine trials. More stringent
respiratory symptom criteria would have lowered our incidence
estimate even further. The low incidence was found in a population where pentavalent vaccine (Pentavac: Diphtheria, Tetanus,
Pertussis [Whole Cell], Hepatitis-B and Haemophilus Type b

Figure 1.

Timing of respiratory episodes.
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Conjugate Vaccine; Serum Institute of India Pvt. Ltd), scheduled for administration at 6, 10, and 14 weeks, is received with
significant delays (7% of infants received all 3 recommended
pertussis vaccines by 6 months) [22]. These data support the
WHO’s recommendation that countries using whole cell pertussis vaccine continue to do so given that the majority of outbreaks have been concentrated in countries using the acellular
pertussis vaccine [2]. Recent studies suggest that protection
from acellular pertussis vaccine is not as strong or long lasting
as that conferred by the whole cell pertussis vaccine [6, 28].
Another contributing factor to the low pertussis incidence
observed could be that surveillance was conducted during a
period of low pertussis transmission. Pertussis is a cyclical disease, thought to peak every 2 to 4 years, and we may have captured the burden at a low circulation period [6]. We observed over
70% of our B pertussis cases over a 1-year period. This increase
from earlier observation periods could indicate a temporary rise
in pertussis consistent with its cyclical pattern or a true increase
in the baseline burden. Previous research on pertussis seasonality has in different places and time periods demonstrated various
periods of peak transmission or no discernable patterns [29, 30].
Although our data do not support a seasonal pattern, the numbers observed are too low to be conclusive.
Pertussis symptom duration and severity were mild compared with the classic pertussis case presentation. Only 3 of
the 17 cases fulfilled the WHO criteria, which requires a minimum of 2 weeks of cough, whoop, or posttussive vomiting [31].
Studies on pertussis in infants have generally been clinic-based,
hospital-based, or in an outbreak, which therefore required a
certain severity of illness for parents to recognize a need for
medical attention [29, 30, 32]. These study designs and passive
surveillance efforts therefore may have missed milder pertussis
cases [33]. Our study, which required only 1 respiratory symptom for a nasal swab to be collected, had increased sensitivity
to detect a range of pertussis case presentations. An alternative explanation for the mild cases seen could be an increase
in the proportion of mild compared with severe pertussis cases
in Nepal.
Although cough, difficulty breathing, and cough with
vomit were the most common symptoms, no symptom was
present in all B pertussis cases. During an epidemic period in
Washington state, among infants <1 year, who had a minimum
of 14 days cough plus an additional symptom, 82% had posttussive emesis, 29% had apnea, 26% had whoop, and 42% had
cyanosis [32]. A study of US neonates with pertussis showed
the symptom prevalence to be 97% for cough, 91% for cyanosis, 58% for apnea, and 3% for fever [34]. Our study found
lower or equal symptom prevalence with the exception of
fever. Fever prevalence was higher in our study, similar to that
found in Peru [29].
Although not statistically significant, infants with pertussis
were more likely to have been born preterm, low birth weight,

Table 2.

Poisson Regression for Risk Factors for Pertussis in Infants
Nonpertussis Infants

Pertussis Infants

Risk Factor

(n = 3466)

(n = 17)

IRR

95% CI

P Value

Male Sex

53%

59%

1.3

0.5 − 3.4

.61

Preterm (<37 weeks)

12%

24%

2.2

0.7 − 6.6

.18

Low birth weight (<2500 grams)

25%

36%

1.7

0.5 − 5.9

.38

Small for gestational age (IG)

37%

50%

1.7

0.5 − 5.8

.41

Small for gestational age (A)

48%

55%

1.3

0.4 − 4.3

.65

Breastfed in 1st hour

35%

38%

1.1

0.4 − 3.0

.86

Primiparous

42%

59%

2.0

0.8 − 5.2

.16

Pahadi ethnicity

58%

69%

1.6

0.6 − 4.6

.37

Literate

61%

60%

1.6

0.6 − 4.6

.37

5

4

0.9

0.7 − 1.1

.39

0.39

0.35

0.2

0.0 − 8.6

.42

Age (days) at first pertussis vaccination (mean)

85

96

1.0

1.0 − 1.0

.17

1st pertussis vaccination received by 6 months

56%

65%

1.5

0.5 − 3.9

.47

Household size (mean)
SES score (mean)

Unadjusted

Abbreviations: A, Alexander standards; CI, confidence interval; IG, INTERGROWTH-21st standards; IRR, incidence rate ratios; SES, socioeconomic status.

and SGA, and their mothers were more likely to be primiparous. These findings are similar to previous studies showing no
difference in pertussis cases by sex [29, 35, 36] or crowding [35]
but showing differences by birth weight [36]. Coinfections were
common, consistent with findings from other hospital-based
studies [33]. Codetection of B pertussis and B parapertussis
with respiratory viruses may be due to asymptomatic pertussis
carriage.
The incidence of B parapertussis of 4 cases per 1000 person-years was comparable to that of 2 per 1000 person-years
found in the Italian acellular pertussis vaccine trial in 1992–
1993 [37]. The duration of illness was shorter for B parapertussis
with a maximum duration of 6 days compared with a maximum
of 33 days for B pertussis. A milder presentation is consistent
with clinical knowledge of B parapertussis infection [37, 38].
Bordetella parapertussis cases occurred only during a 5-month
period.

symptom in isolation without also having one of the originally specified respiratory symptoms. These data support our
assumption that we were unlikely to have missed pertussis cases
in year 1 with our less sensitive respiratory symptom criteria.
Nasal swabs were collected in the mid-nasal region for
influenza virus detection, which may have lowered the sensitivity of pertussis detection. In a field site, the acceptability of
an additional nasopharyngeal swab would likely have increased
the participant refusal rate. This would have decreased the generalizability of our results to the entire population. Although
nasopharyngeal swabs or nasopharyngeal aspirates are the recommended specimen collection method [39], the nasopharyngeal region was established as the collection area of choice when
the diagnostic measure was culture, which has low sensitivity.
Recent data demonstrated the comparability of using mid-nasal
versus nasopharyngeal swabs in PCR pertussis detection [40].
Strengths

Limitations

There were several study design limitations. We cannot be certain whether the reported symptoms were caused by pertussis,
another organism, or whether symptoms were related to 2 or
more etiologic agents. We were unable to perform multivariate
regression modeling for characteristics associated with pertussis disease and pertussis cases due to the small number of cases
we detected.
Infant respiratory symptoms were reported by parents, who
may have missed signs that might have been observed by a
healthcare worker. However, the criteria for collection of the
nasal swab were broad and did not require sophisticated clinical
skills. However, apnea and cyanosis may have been difficult for
parents to identify. Although the criteria for specimen collection
changed in year 2, no infant experienced a pertussis-specific

Strengths of the study included being a population-based, prospective study, with very low refusal rates. Risk factors, clinical symptoms, and coinfections were prospectively identified
without the potential bias that may occur when these data
are collected retrospectively or in clinical settings. The community-based design allows generalizability of these results
to the entire population and not just those seeking care at a
health facility or in an outbreak situation. The Sarlahi District
is located in the Terai region where the majority of Nepalese
reside, and it has similar demographics to the entire population
of Nepal [41]. Sarlahi’s location near sea level and on the border
with India supports the generalizability of these results to many
populations living on the Indian subcontinent. The weekly
active surveillance with sensitive criteria for pertussis testing
was able to detect mild and atypical pertussis cases, which may
Infant Pertussis Incidence in Nepal • JPIDS 2017:6 (March) • 37
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have been missed by previous traditional surveillance. The
multitarget PCR method allowed highly sensitive and specific
detection of 2 additional Bordetella species beyond the primary
B pertussis target.

9.

10.

CONCLUSIONS

We observed a low incidence of pertussis in infants in a whole
cell vaccine environment. Pertussis cases were generally milder
than expected compared with traditional pertussis clinical definitions. These data support clinicians considering pertussis
in their differential diagnosis of infants with mild respiratory
symptoms. Policymakers in Nepal will need to weigh the benefit
of an additional prenatal pertussis vaccine or a switch to acellular primary pertussis vaccine with the low burden of pertussis
in infants less than 6 months.
Our study demonstrated that mid-nasal swabs were able
to detect pertussis using a sensitive multitarget PCR. The less
invasive mid-nasal nasal swab is an attractive alternative for
pertussis nasal swab collection, and further research is needed
to compare this collection site with nasopharyngeal swabs. In
the future, this method may enhance population-based surveillance efforts.
Supplementary Data

11.

12.
13.
14.
15.

16.

17.
18.
19.

20.

Supplementary materials are available at Journal of the Pediatric Infectious
Diseases Society online.
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